The Pharma Letter features a major milestone for Dewpoint Therapeutics – the nomination of our first development candidate, DPTX3186, as a potential therapeutic agent for treatment of Wnt-driven cancers.
Design: SALIENCE Communication / Publiepress
Scientific animation: Visual Science